Kineta Inc.
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (m… Read more
Kineta Inc. (KA) - Net Assets
Latest net assets as of June 2024: $-7.98 Million USD
Based on the latest financial reports, Kineta Inc. (KA) has net assets worth $-7.98 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.40 Million) and total liabilities ($9.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.98 Million |
| % of Total Assets | -570.34% |
| Annual Growth Rate | -52.94% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 50.74 |
Kineta Inc. - Net Assets Trend (2019–2023)
This chart illustrates how Kineta Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kineta Inc. (2019–2023)
The table below shows the annual net assets of Kineta Inc. from 2019 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $3.06 Million | -33.06% |
| 2022-12-31 | $4.57 Million | +138.25% |
| 2021-12-31 | $-11.95 Million | +44.54% |
| 2020-12-31 | $-21.55 Million | -134.54% |
| 2019-12-31 | $62.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kineta Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 17087100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.35% |
| Other Components | $168.67 Million | 5836.30% |
| Total Equity | $2.89 Million | 100.00% |
Kineta Inc. Competitors by Market Cap
The table below lists competitors of Kineta Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Megapolitan Developments Tbk
JK:EMDE
|
$3.83 Million |
|
Sahathai Terminal Public Company Limited
BK:PORT
|
$3.84 Million |
|
ADV. SOLTEC.SWE. AB 10/21
F:7ST0
|
$3.84 Million |
|
Hultström Group B
ST:HULT-B
|
$3.85 Million |
|
Group 6 Metals Ltd
AU:G6M
|
$3.83 Million |
|
Venari Minerals NL
AU:VMS
|
$3.83 Million |
|
Saigon Garment Manufacturing Trade JSC
VN:GMC
|
$3.83 Million |
|
CytoMed Therapeutics Limited Ordinary Shares
NASDAQ:GDTC
|
$3.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kineta Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,424,000 to 2,890,000, a change of -1,534,000 (-34.7%).
- Net loss of 14,099,000 reduced equity.
- New share issuances of 13,663,000 increased equity.
- Other factors decreased equity by 1,098,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.10 Million | -487.85% |
| Share Issuances | $13.66 Million | +472.77% |
| Other Changes | $-1.10 Million | -37.99% |
| Total Change | $- | -34.67% |
Book Value vs Market Value Analysis
This analysis compares Kineta Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $170.77 | $0.48 | x |
| 2020-12-31 | $-64.63 | $0.48 | x |
| 2021-12-31 | $-8.26 | $0.48 | x |
| 2022-12-31 | $0.90 | $0.48 | x |
| 2023-12-31 | $0.26 | $0.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kineta Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -487.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -259.08%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 3.56x
- Recent ROE (-487.85%) is below the historical average (-401.64%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -94.79% | -1182.50% | 0.06x | 1.36x | $-65.36 Million |
| 2020 | 0.00% | -132.31% | 0.73x | 0.00x | $-11.70 Million |
| 2021 | 0.00% | -131.56% | 0.68x | 0.00x | $-10.75 Million |
| 2022 | -1425.57% | -3229.24% | 0.11x | 3.94x | $-63.51 Million |
| 2023 | -487.85% | -259.08% | 0.53x | 3.56x | $-14.39 Million |
Industry Comparison
This section compares Kineta Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kineta Inc. (KA) | $-7.98 Million | -94.79% | N/A | $3.83 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |